Reliv International, Inc. (NASDAQ:RELV), a developer and marketer of nutritional supplements that promote optimal health, today reported its financial results for the first quarter of 2020.
CHESTERFIELD, Mo. , Nov. 14, 2019 /PRNewswire/ -- Reliv International, Inc. (NASDAQ:RELV), a marketer of nutritional supplements that promote optimal health, today reported its financial results for the ...
Statistically speaking, long term investing is a profitable endeavour. But that doesn't mean long term investors can...
CHESTERFIELD, Mo., Aug. 7, 2019 /PRNewswire/ -- Reliv International, a 30-year-old wellness company located in Chesterfield, MO, announced today that Dr. Alfredo Galvez has been appointed as the company's Chief Scientific Advisor. Galvez has been associated with Reliv since 2013 and is best known for his groundbreaking work with lunasin, a naturally occurring soy peptide. Through scientific research and clinical trials, Galvez has proven that lunasin affects gene expression and is the first dietary ingredient shown to promote optimal health at the epigenetic level. Galvez serendipitously discovered the soy peptide in 1996 as a postdoctoral researcher at UC Berkeley. He has a PhD in Genetics from UC Davis, majoring in molecular biology and cytogenetics. After completing his PhD, Galvez worked for the USDA-ARS at Washington State University and at the University of California Berkeley as a Research Biochemist and Geneticist.
Reliv International, Inc. (NASDAQ:RELV), a maker of nutritional supplements that promote optimal health, today reported its financial results for the fourth quarter and full year of 2019.
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
CHESTERFIELD, Mo. , Aug. 9, 2019 /PRNewswire/ -- Reliv International, Inc. (NASDAQ:RELV), a maker of nutritional supplements that promote optimal health, today reported its financial results for the second ...
The main aim of stock picking is to find the market-beating stocks. But in any portfolio, there will be mixed results...